priors.science/reviews/lipid-management-cardiovascular-risk

Lipid Management Cardiovascular Risk

The current evidence on 18 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

18claims tracked
145primary papers reviewed
9 Aug 2026latest evidence review
Weeklyre-scored against new papers
8 Established · 9 Likely · 1 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
ClaimStandingEvidence certaintyCorpus
Bempedoic acid for statin-intolerant patientsNovel Lipid AgentsEstablished90%11
RNA interference reduces lipoprotein(a) levelsNovel Lipid AgentsEstablished89%9
Elevated lipoprotein(a) predicts cardiovascular eventsResidual Lipid RiskEstablished87%14
Statins reduce major cardiovascular eventsStatin TherapyEstablished87%8
Low-density lipoprotein cholesterol targets underachieved in practiceLDL TargetsEstablished87%11
Statins in primary preventionStatin TherapyEstablished86%11
PCSK9 inhibitors reduce major adverse cardiovascular events in atherosclerotic cardiovascular diseasePcsk9 InhibitorsEstablished85%13
Early PCSK9 inhibitor timing after acute coronary syndromePcsk9 InhibitorsEstablished85%4
Non-high-density lipoprotein cholesterol residual risk beyond low-density lipoprotein cholesterolResidual Lipid RiskLikely83%7
Statin plus ezetimibe versus high-intensity statinCombination TherapyLikely81%6
Inclisiran biannual low-density lipoprotein cholesterol loweringPcsk9 InhibitorsLikely81%9
Apolipoprotein B versus low-density lipoprotein cholesterol for atherosclerotic cardiovascular disease predictionResidual Lipid RiskLikely81%8
PCSK9 inhibitors lower lipoprotein(a) and low-density lipoprotein cholesterolNovel Lipid AgentsLikely80%7
High-intensity statin major adverse cardiovascular event benefitStatin TherapyLikely80%6
Remnant cholesterol predicts residual cardiovascular disease riskResidual Lipid RiskLong-standingLikely79%9
Ezetimibe plus statin versus statin aloneCombination TherapyLong-standingLikely74%10
Low-density lipoprotein cholesterol 55 versus 70 mg/dL targetLDL TargetsLikely71%5
Early ezetimibe after myocardial infarction benefitCombination TherapyLong-standingUncertain65%8
Track Lipid Management Cardiovascular Risk.
These claims are re-scored against new papers every week. Track this topic for the full review, including each claim’s challenge and the papers behind it.
Track this topic →
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely70–84%Well supported, with some gaps or indirect evidence.
Uncertain50–69%Mixed or limited evidence. Genuinely open.
Doubtful30–49%Little support; the weight of evidence leans against it.
Refuted< 30%The evidence contradicts it — confidently false as stated.
Where the evidence sits in time
Long-standingMost of this evidence is older than the rest of this field.